| abstract |
Aspects and embodiments of the invention relate to the treatment of neurological disorders such as Alzheimer's and Parkinson's. In particular, some embodiments relate to disorder GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. In addition, the present invention also includes pharmaceutical compositions containing GIP/GLP-1 co-agonist peptides, as well as methods of treating these diseases and other subject matter. |